Hold AMGN with 10-15% tactical trim at $416; preserve core exposure given confirmed post-earnings regime change and accelerating fundamentals
The decision anchors to the explicit lesson from the Aug 11 Underweight call: when technicals and fundamentals conflict in a confirmed post-earnings regime change, weight fundamental acceleration as the dominant variable and reduce trim magnitude accordingly. The 10-15% tactical trim acknowledges the overbought setup (RSI 72.22, ~12% fair-value gap) without surrendering structural exposure earned through the regime change. The residual 85-90% position is protected by a real stop at $410, not the flawed $431 reference. Re-entry at $400-410 or $367 provides confirmation-based risk management. Q3 2026 earnings is the next major inflection for full position re-evaluation.
| Position | Action |
|---|---|
| Current position — tactical trim 10-15% into $416 area | Reduce to 85-90% of original weight |
| Re-entry in $400-410 zone (10 EMA/prior consolidation) | Buy-limit orders at 50-75% of trimmed size |
| Re-entry at $367 (50 SMA) — higher conviction re-engagement if breakout fails cleanly | Deploy deeper allocation |
| Breakout confirmation: AMGN closes above $431 on volume >4M shares | Top up residual position toward full weight |
AMGN's bullish breakout is supported by accelerating fundamentals (9.5% revenue growth, raised guidance), confirmed technical momentum (no bearish divergence, 5.75M share volume bar), below-peer valuation (forward P/E 17.18), and favorable macro/sector rotation favoring defensive dividend payers with growth catalysts.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 403.55 | bullish |
| close_50_sma | 366.89 | bullish |
| close_200_sma | 345.27 | bullish |
| macd | 14.21 | bullish |
| macds | 11.48 | bullish |
| macdh | 2.73 | bullish |
| rsi | 72.22 | neutral |
| boll | 387.59 | neutral |
| boll_ub | 424.52 | neutral |
| boll_lb | 350.66 | neutral |
| atr | 11.46 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price pulls back to $400-410 zone (10 EMA/prior consolidation)
Then: Buy-limit orders at 50-75% of trimmed size
Technical breakout confirmed by momentum indicators with no bearish divergence
· concedes: RSI overbought at 72.22 is a caution flag on entry sizing, not a reversal signal; Volume is decelerating off the breakout (normal post high-conviction volume bar); Retail data absence is irrelevant for a $225B institutional name; Obesity candidate abandonment means no direct GLP-1 market participation; Buybacks paused removes per-share support mechanism
AMGN at $416.18 is a trap for late entrants—trading at all-time highs with RSI 72.22, collapsed volume (70% drop from breakout), zero margin of safety (12% above fair value), and a forward EPS target of $24.22 that requires flawless execution against a 30% legacy revenue block facing biosimilar erosion, an abandoned obesity franchise, and a balance sheet already stretched by $43B net debt.
· concedes: AMGN is a fundamentally high-quality company; The August 5th breakout was a legitimate technical event; The six growth drivers do currently represent ~70% of sales; Q2 earnings beat and guidance raise were real events; The 0.41 beta does provide protection in equity drawdowns; A pullback to $367–387 would reset risk/reward and offer a higher-probability entry
→ vs conservative: Waiting for pullback is 'indecision dressed up as discipline'—the stock is too extended to sit on a position at all-time highs near $416.18 with Bollinger resistance just above
→ vs conservative: The 'don't fight the trend' argument misses tactical exhaustion—textbook bullish alignment doesn't mean holding through RSI 72.22 near resistance
→ vs conservative: The 'volume confirmation is intact' take ignores 70% volume decay since breakout—momentum is leaking, not building
→ vs conservative: Biosimilar headwinds are 'manageable' framing understates 30% legacy revenue erosion; new growth drivers don't fully offset structural decline
→ vs neutral: HOLD stance implicitly bets AMGN will continue to defy its own $371.93 fair value target while trading at $416.18—financing a directional bet with capital
→ vs neutral: Neutral analyst's own framework targets $370-$375 fair value zone, meaning current $416 price already exceeds the reward target
→ vs conservative: Higher-for-longer rate argument for defensive dividend payers ignores that the defensive bid is already exhausted at all-time highs and Bollinger resistance
| vwma | 394.31 | bullish |
Support: 403.55 · 393.1 · 387.59 · 366.89 · 350.66 · 345.27 | Resistance: 424.52 · 430
AMGN exhibits a textbook bullish moving average stack (10 EMA 403.55 > 50 SMA 366.89 > 200 SMA 345.27) across all timeframes. Price at 416.18 is ~13.4% above the 50 SMA and ~20.5% above the 200 SMA, confirming a firmly established uptrend. The late July rally (+9.7% in 9 sessions) was followed by an early August breakout on 5.75M shares, the highest volume of the window. MACD (14.21) is above signal (11.48) with histogram +2.73 and no bearish divergence, confirming momentum expansion. However, RSI at 72.22 is above the 70 overbought threshold and price is ~2.0% below the Bollinger upper band (424.52), warranting caution. Volume is decelerating post-breakout, typical late-stage behavior. The recommended action is HOLD on existing positions; fresh entries should wait for pullbacks to 393–403 with RSI resetting to 55–65.
Market Cap
$225.15B
P/E (TTM)
25.82
Forward P/E
17.18
PEG Ratio
2.19
Price/Book
19.25
EV/EBITDA (TTM)
~15.5
Dividend Yield
2.43%
Revenue (TTM)
$38.09B
Q2 2026 Total Revenue
$10.05B
Q2 2026 Operating Revenue
$9.54B
Gross Margin (Q2 2026)
~72%
Operating Margin
35.55%
Net Profit Margin
22.95%
EPS (TTM)
$16.12
Forward EPS
$24.22
Q2 2026 EPS
$4.37
Q2 2026 Net Income
$2.375B
Effective Tax Rate
14.2%
R&D (Q2 2026)
$1.87B
SG&A (Q2 2026)
$1.74B
Free Cash Flow (TTM)
$8.65B
Q2 2026 FCF
$3.49B
Q2 2026 OCF
$4.00B
YTD 2026 CapEx
$1.23B
CapEx as % Revenue (Q2 2026)
~5.1%
Dividends Paid (Q2 2026)
$1.36B
Annual Dividend (est.)
~$5.4B
Payout Ratio (FCF basis)
~45%
Total Assets
$95.64B
Total Debt
$57.30B
Cash & Equivalents
$13.99B
Net Debt
$43.32B
Stockholders' Equity
$11.69B
Tangible Book Value
-$27.47B
Goodwill & Intangibles
$39.16B
Working Capital
$9.46B
Current Ratio
1.37
Net Debt/EBITDA
~2.5x
Annual Interest Expense (est.)
~$2.7B
ROE
91.47%
ROA
8.67%
Beta
0.413
52-Week High
$421.79
52-Week Low
$269.77
50-Day MA
$365.15
200-Day MA
$347.52
Strengths
Concerns
AMGN is a financially healthy, cash-generative biotech with accelerating revenue (+9.5% YoY in Q2 2026 to $10.05B) and improving margins (Operating Margin 35.55%, Net Margin 22.95%). The company is actively deleveraging (Net Debt declining 10% YoY to $43.32B) while maintaining a sustainable dividend (2.43% yield, ~45% FCF payout ratio). The stock is rated HOLD — attractive on weakness near/below the 200-day MA for income-oriented investors given its defensive 0.41 beta, but the absence of active buybacks and PEG > 2 limit near-term upside catalysts.
Macro: Higher-for-longer rate environment with no Fed cuts in 2026 priced at 86% (down 2.2pp WoW) per Polymarket. No US recession by year-end priced at 92% (recession odds at 8%, down 1.0pp WoW). Deep-cut scenarios (≥6 cuts) price near 0%. Macro backdrop is mildly supportive for Amgen as a defensive income play with lower duration sensitivity than biotech disruptors, but slightly negative in absolute terms due to higher discount rates limiting multiple expansion. FRED data unavailable; no fabricated values used. Inflation context: global trackers show Japan core CPI ≤1.9% at 49%, UK 3.5–3.9% at 27%, Eurozone 1.9–2.1% at 1% — non-US context only. Tape: WSJ noted mixed US stocks after inflation data and AI earnings; Reuters noted oil prices climbing while equities gained; IBD flagged Dow record close mid-week. Constructive backdrop for large-cap quality cyclicals and defensives.